Glucagon-like peptide-2 analogue
Teduglutide
An established GLP-2 medicine that can reduce parenteral-support needs in short bowel syndrome, with intensive product-specific monitoring.
Also known as Gattex · ALX-0600 · GLP-2 analogue
01 · Evidence profile
One molecule, four evidence questions
Randomized trials support reduction in parenteral-support requirements for short bowel syndrome.
Intestinal absorption, exposure, and product effects are characterized in the label and trials.
The label addresses neoplastic growth, obstruction, biliary and pancreatic disease, and fluid imbalance.
High for authentic Gattex used within its monitoring program.
02 · Identity
What it is
Teduglutide is a DPP-4-resistant analogue of GLP-2 that promotes intestinal absorptive capacity. Gattex is approved for people with short bowel syndrome who depend on parenteral support.
03 · Product identity
The molecule is not the finished product.
Gattex is a labeled prescription product used with structured monitoring. Its evidence does not establish general gut healing or equivalence for compounded GLP-2 analogues.
Gattex
2025 label- Formulation
- Powder and diluent for injection
- Route
- Subcutaneous
- Indication scope
- Short bowel syndrome with parenteral-support dependence in the adult and pediatric populations defined in the label.
- Gattex
- Short bowel syndrome with dependence on parenteral support in labeled adults and children
04 · Evidence snapshot
What the evidence can and cannot say
Randomized trials found reductions in parenteral fluid or nutrition requirements for some participants. The product label defines required screening and ongoing monitoring.
The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.
05 · Claim check
Three claims under the lens
“Teduglutide can reduce parenteral-support needs in short bowel syndrome.”
Controlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults and labeled pediatric populations with short bowel syndrome dependent on parenteral support.
“Teduglutide is a general gut-healing peptide.”
The approved indication and outcome are specific to short bowel syndrome with parenteral-support dependence.
- Evidence basis
- Regulatory or product record
- Scope
- The current Gattex indication.
“Because teduglutide promotes intestinal growth, it is low risk.”
The same biological activity underlies important warnings, including potential acceleration of neoplastic growth.
- Evidence basis
- Regulatory or product record
- Scope
- Approved Gattex use with required screening and monitoring.
06 · Safety boundary
Before this becomes personal
Potential acceleration of neoplastic growth and other serious risks make this a monitored prescription therapy. No dosing, reconstitution, or self-treatment guidance is provided.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Initial brief based on the 2025 Gattex label, randomized trial, and orphan-drug record.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.